Seven Fleet Capital Management LP Has $11.90 Million Stock Holdings in Assembly Biosciences, Inc. $ASMB

Seven Fleet Capital Management LP boosted its stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) by 671.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 433,147 shares of the biopharmaceutical company’s stock after buying an additional 377,000 shares during the quarter. Assembly Biosciences makes up approximately 2.0% of Seven Fleet Capital Management LP’s portfolio, making the stock its 10th biggest position. Seven Fleet Capital Management LP’s holdings in Assembly Biosciences were worth $11,903,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. RA Capital Management L.P. acquired a new stake in shares of Assembly Biosciences in the third quarter valued at about $26,122,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Assembly Biosciences in the fourth quarter worth approximately $22,625,000. Parkman Healthcare Partners LLC acquired a new position in shares of Assembly Biosciences in the third quarter worth approximately $6,425,000. Vanguard Group Inc. boosted its holdings in Assembly Biosciences by 97.8% in the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after acquiring an additional 248,287 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Assembly Biosciences in the fourth quarter valued at approximately $5,476,000. Institutional investors own 19.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Zacks Research upgraded shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Guggenheim reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. Mizuho set a $45.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research note on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $35.42 on Thursday. Assembly Biosciences, Inc. has a one year low of $20.23 and a one year high of $39.71. The stock’s 50-day moving average is $27.81 and its 200 day moving average is $27.79. The firm has a market cap of $721.15 million, a price-to-earnings ratio of 34.73 and a beta of 1.10.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.52. The business had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. On average, sell-side analysts expect that Assembly Biosciences, Inc. will post 2.28 EPS for the current fiscal year.

Assembly Biosciences Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.